Although the cohort study of SLE patients and mouse influenza models suggest a significant benefit of Ld-IL2 therapy for infection control, the revelation of deteriorated inflammation and organ damages by IL-2 treatment in the mouse model of LCMV infection represents an important alarming issue for patients with hyper-reactive CD8+ T cell immune response. This evidence concerns the gene CD8A and systemic lupus erythematosus.